Our Team

Xavier Fernández-Busquets started his undergraduate research career as a trainee student (1985 and 1986) in Organic Chemistry and Enzymology at the CIBA-GEIGY Zentrale Forschungslaboratorien in Basel, Switzerland. He graduated in Biology (Biochemistry specialization) at the Universitat Autònoma de Barcelona (1986), where he also obtained his PhD in the field of Molecular Biology (1992).

Between 1992 and 2001 he held several postdoctoral positions, among which those at the Friedrich Miescher Institut (Novartis AG, Basel) and at the Woods Hole Marine Biological Laboratory (Massachusetts, US), where he worked on the evolutionary origins of specific cell adhesion and started his training in Nanotechnology.

After returning to Spain with a postdoctoral contract (Universitat de Barcelona, 1999), he obtained in 2001 a 5-year tenure track Ramón y Cajal position at the Universitat de Barcelona where he led a group focused on nanotechnological approaches to amyloid diseases and malaria. After obtaining the I3 accreditation, he became in 2006 Senior Researcher at the Institute for Bioengineering of Catalonia (IBEC) and since 2010 he is Head of the Nanomalaria Joint Unit (IBEC/Barcelona Institute for Global Health, ISGlobal).

Lines of research

• Development of nanovectors for the targeted drug delivery of antimalarials.With the advent of nanoscience, renewed hopes have appeared of finally obtaining the long sought-after magic bullet against malaria. The use of overall drug doses sufficiently low to avoid side effects, but which locally are high enough to be lethal for the parasite, will contribute to reduce the evolution of parasite resistance and thus increase drug efficacy. The nanomalaria group works on the design of prototype nanovectors for the targeted delivery of antimalarial drugs exclusively to Plasmodium-infected cells, capable of reaching the preclinical pipeline in the short term. The three variables being explored are the type of encapsulating structure, the targeting molecule, and the antimalarial compound itself, in order to assemble a Troyan horse nanocapsule targeting with complete specificity parasitized cells, of delivering inside them its antimalarial cargo, and of eliminating detectable parasitemia both in Plasmodium cultures and in mouse and mosquito malaria models. Benefits and drawbacks of the different nanovector elements are considered, including cost-related issues and the ethics of possible constraints that might be hampering the development of nanotechnology-based medicines against malaria with the dubious argument that they are too expensive to be used in developing areas.

Main publications

• Avalos-Padilla Y, Bouzón-Arnáiz I, Ramírez M, Camarero-Hoyos C, Orozco-Quer M, M Arce E, Muñoz-Torrero D, Fernàndez-Busquets X. Overexpression in Plasmodium falciparum of an intrinsically disordered protein segment of PfUT impairs the parasite's proteostasis and reduces its growth rate. Front Cell Infect Microbiol. 2025 May 13;15:1565814. doi: 10.3389/fcimb.2025.1565814.
• Bouzón-Arnáiz I, Rawat M, Coyle R, Feufack-Donfack LB, Ea M, Orban A, Popovici J, Román-Álamo L, Fallica AN, Domínguez-Asenjo B, Moreno J, Arce EM, Mallo-Abreu A, Muñoz-Torrero D, Lee MCS, Fernàndez-Busquets X. YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates. Sci Rep. 2025 Jan 23;15(1):2941. doi: 10.1038/s41598-025-85346-y.
• Camarero-Hoyos C, Bouzón-Arnáiz I, Avalos-Padilla Y, Fallica AN, Román-Álamo L, Ramírez M, Portabella E, Cuspinera O, Currea-Ayala D, Orozco-Quer M, Ribera M, Siden-Kiamos I, Spanos L, Iglesias V, Crespo B, Viera S, Andreu D, Sulleiro E, Zarzuela F, Urtasun N, Pérez-Torras S, Pastor-Anglada M, Arce EM, Muñoz-Torrero D, Fernàndez-Busquets X. Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy. Pharmaceutics. 2024 Sep 30;16(10):1290. doi: 10.3390/pharmaceutics16101290.
• Román-Álamo L, Avalos-Padilla Y, Bouzón-Arnáiz I, Iglesias V, Fernández-Lajo J, Monteiro JM, Rivas L, Fisa R, Riera C, Andreu D, Pintado-Grima C, Ventura S, Arce EM, Muñoz-Torrero D, Fernàndez-Busquets X. Effect of the aggregated protein dye YAT2150 on Leishmania parasite viability. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112723. doi: 10.1128/aac.01127-23.
• San Anselmo M, Lantero E, Avalos-Padilla Y, Bouzón-Arnáiz I, Ramírez M, Postigo A, Serrano JL, Sierra T, Hernández-Ainsa S, Fernàndez-Busquets X. Heparin-Coated Dendronized Hyperbranched Polymers for Antimalarial Targeted Delivery. ACS Appl Polym Mater. 2022 Dec 30;5(1):381-390. doi: 10.1021/acsapm.2c01553.